ArticleFrontiers in genetics2025
Integrative multi-omics analysis and machine learning reveal the unique role of ASCC3 in combination with various immune-related genes in rectal adenocarcinoma.
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- ASCC3 promotes chemosensitivity in colorectal cancer cells.Scientific reports · 2026Article
- High COMP expression promotes tumor cell proliferation and migration of rectal cancer, contributing to unfavorable prognosis and suppressive immune microenvironment.Discover oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Activating Signal Cointegrator 1 (ASC-1) complex is a tetrameric complex composed of Thyroid Hormone Receptor Interactor 4 (TRIP4), Activating Signal Cointegrator 1 (ASCC1), Activating Signal Cointegrator 2 (ASCC2), and Activating Signal Cointegrator 3 (ASCC3). As the core subunit of the ASC-1 complex, ASCC3 is involved in DNA damage repair. However, the exact role of ASCC3 in digestive system cancers, particularly in rectal adenocarcinoma (READ), remains unclear. Methods: We utilized data from The Cancer Genome Atlas (TCGA) and GEO to investigate the prognostic value of the four subunits, with a focus on ASCC3, in pan-cancers including rectal adenocarcinoma. Additionally, we explored the regulatory mechanisms of ASCC3 and its association with tumor immunity in rectal adenocarcinoma using TIMER, IMMPORT, DAVID databases, and CIBERSORT analysis. Prognostic models were constructed using ssGSEA analysis and various machine learning algorithms. We explored the signaling pathways regulated by ASCC3 using the CancerSEA and TCPA databases. Furthermore, mutations of ASCC3 in pan-cancer were investigated using the PFAM and CbioPortal databases. Finally, we performed interaction network analysis of ASCC3 using STRING, ComPPI, and BioGRID databases. Results: ASCC3 is a specific protective factor for rectal adenocarcinoma across various cancer types, particularly in digestive system cancers, and can synergize with several immune-related genes, including JAK1, NFKB1, SEMA5A, NR2C2, CNTF, and CREB1, to influence patient prognosis. Furthermore, ASCC3 may regulate tumor immunity by affecting T cell function. Conclusion: ASCC3 can serve as an independent prognostic factor for READ and can synergize with various immune-related genes to influence patient prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.